SCHEMBL941049

SCHEMBL941049

CCOC(=O)c1cccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c1O

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 3/20 0.60
TYR P14679 2/20 0.55
SLC5A2 P31639 5/20 0.53
SLC5A1 P13866 3/20 0.53
HIF1A Q16665 1/20 0.50
TYMP P19971 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL940123 0.91 SLC28A3 (0.57) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL942732 0.88 SLC28A3 (0.62) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL7780293 0.87 SLC28A3 (0.53) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL7773544 0.87 SLC28A3 (0.53) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL941797 0.85 SLC28A3 (0.58) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL4636160 0.85 SLC28A3 (0.58) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL943236 0.85 SLC28A3 (0.74) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL941002 0.84 SLC28A3 (0.62) SLC28A3TYRSLC5A2SLC5A1HIF1A
SCHEMBL4635348 0.82 SLC28A3 (0.56) SLC28A3TYRSLC5A2SLC5A1
SCHEMBL4636842 0.82 TYR (0.53) SLC28A3TYRSLC5A2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE DSM IP ASSETS B.V. (NL) 2011-01-20 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-1859835-A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM Ltd. (CH) 2007-11-28 EP disclosed
US-20030198610-A1 Topical agent for dermatological use DSM IP ASSETS B.V. (NL) 2003-10-23 US disclosed
EP-0649648-B1 Skin whitening agents containing glycosides SHISEIDO CO LTD (JP) 2001-09-19 EP disclosed
US-5700784-A GLYCOSIDES OF HYDROXYSALICYLIC ACID AND/OR GLYCOSIDES OF ESTERS OF HYDROXYSALICYLIC ACID; EXCELLENT WHITENING EFFECT AND SKIN CARE EFFECT SHISEIDO CO., LTD. (JP) 1997-12-23 US disclosed
EP-0649648-A2 Skin whitening agents containing glycosides SHISEIDO COMPANY LIMITED (JP) 1995-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE GALE, ALPP, UGGT1 SLC28A3 2245/4885TYR 9/4885SLC5A2 1353/4885
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885TYR 149/4885SLC5A2 553/4885
US-20030198610-A1 Topical agent for dermatological use GALE, UGGT1, UGDH SLC28A3 2040/4885TYR 6/4885SLC5A2 1116/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885TYR 113/4885SLC5A2 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.